Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We believe the data showing an overall survival advantage over standard of care would be encouraging |
| Responses were also achieved in the hard-to-treat high-grade serous adenocarcinoma patients, along with a favorable safety profile |
| Henry has been instrumental for the successful transition of Compugen from a preclinical to clinical stage company and creating the growth opportunities in front of us |
| To summarize, 2023 was a very successful year for Compugen, both on the execution front and the validation of our computation discovery and development capabilities, including the exciting preclinical license deal with Gilead for our IL-18 BP immunology program, the initiation of two proof-of-concept studies in presentation of preliminary predictive biomarker data with our unique and innovative triple IO combination and progress by our partner at AstraZeneca initiating a Phase III trial with rilvegostomig |
| Our accomplishments in 2023 position us well for catalyst to reach 2024 and with an extended cash runway expected into 2027, which we believe will support the development of our clinical assets and novel early-stage pipeline |
| Michelle is an excellent fit for Compugen and will be a great partner to me and a collaborator to the whole team as we work together on executing our programs to accelerate value creation |
| Our successes in 2023 and in the last quarter, in particular, position us well as we advance into 2024 and are expected to play an important role in the exciting future and vision for Compugen |
| We believe that these are good partnering opportunities |
| You can test it in single-arm studies, but one cannot ignore that these assets have a potential in the inflamed tumor type and this is a great opportunity based on the data that we have and the data that we have supporting COM701 driven effect, we believe that it could serve as good partnering opportunities |
| I'm delighted to say that we advanced into 2024 with a solid balance sheet |
| Finally, the cash received from our licensing deal with Gilead, a milestone met by AstraZeneca in 2023 allow us to move into 2024 with a solid balance sheet |
| So and this is what we're testing, right, the triplet combination, which is an IO, pure combination, extremely safe, very good tolerability profile and hope to see the signals mature, and we'll share it later this year |
| Before handing over to Alberto to go through our financials, I want to emphasize that we will continue to be financially disciplined, while benefiting from our solid cash position to enhance and advance our company |
| The deal process was competitive, which reflects the significant interest in the IL-18 space and highlights the potential of our COM503's differentiated antibody approach |
| And finally, our focus remains on non-diluted funding for which we have demonstrated in 2023, we can successfully execute on |
| And together, we're well advanced on the Phase I trial design and feel confident that we can initiate Phase I shortly after we gain IND clearance |
| It gives us an edge |
| This is a result of competent accomplishments on the collaboration front in 2023, securing non-dilutive funding, which was always our priority |
| Totally agree, looking forward to seeing how the catalyst play out this year, this will be a very interesting year for the company |
| It is also a testament to the differentiation of our antibody program targeting the IL-18 binding protein |
| The additional cash we received and the cash we expect to receive upon IND clearance of COM503 is expected to extend our cash runway from the end of 2024 into 2027 and potentially accelerate value creation by enabling us to invest in enhancing our discovery capabilities and advancing our diversified portfolio, including our differentiated COM701, COM902, IO combination strategy, the Phase I development of COM503 and our early-stage innovative pipeline |
| Based on the encouraging safety and efficacy data generated to date, with our COM701 combination across indications, we believe there is an opportunity to collaborate with potential partners to bring COM701 combination to patients across a broad range of indications, generating a potentially large opportunity |
| We believe the totality of the data reported in these patients is encouraging compared to the current standard of care |
| I would like to thank all our colleagues here as confidence for their passion and commitment to our success in 2023 and their dedication and readiness to drive for success in 2024 |
| Regarding NSCLC, in the first cohort of 22 patients treated with COM701 in combination with nivolumab, we showed an encouraging overall response rate of 12% and stable diseases in patients with liver metastases, a patient population, which historically has not responded to other drugs |
| I'm really excited to welcome Michelle, an oncologist by training, with extensive experience in leading clinical development in both biotech and pharma companies in and outside of the US |
| And hopefully the TIGIT data that is out there and that will be out there by the companies that are leading this field will allow us to clear the air for TIGIT at least to understand that there is a benefit by adding TIGIT to PD-1 and that there is a third component that is needed |
| While we believe that these indications represent a very high bar, we have previously presented encouraging clinical data, supported by immune activation, suggesting that the unique biology of PVRIG enables anti-PD-1 activity in this challenging indications |
| AstraZeneca's broad clinical investigation of this asset across multiple indications and across various lines of treatment and combinations increases on probability of realizing future milestone payments and royalties |
| The ongoing study fully recruited in 2023 at a speed which we believe reflects the significant unmet need |
| Statement |
|---|
| These are particularly challenging indications to treat and have historically failed to respond to neurotherapy |
| In MSS-CRC, the bar is very high due to the many failures and the nonresponsive nature of the liver metastasis patient population |
| I know that there's probably some scarcity value around that so |
| Finally, on net loss |
Please consider a small donation if you think this website provides you with relevant information